Annual report pursuant to Section 13 and 15(d)

Organization and Description of the Business (Details Narrative)

v3.19.1
Organization and Description of the Business (Details Narrative) - USD ($)
 12 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Oct. 04, 2017
Dec. 31, 2018
Number of shares acquired in exchange for common stock   31,745,242   2,090,301
Precentage of issued and outstanding common stock diluted basis   90.00%    
Promet [Member]        
Precentage of issued and outstanding common stock diluted basis   84.00%    
CoNCERT Pharmaceuticals, Inc [Member]        
Number of shares acquired in exchange for common stock 2,090,301      
Precentage of issued and outstanding common stock diluted basis   6.00%    
Option exercised in exchange for common stock $ 8,000,000      
Percentage of common stock holdings 5.93%      
Percentage of royalty 15.00%      
Proceeds from royalty receivable     $ 8,000,000  
Controlling interest, description Promet’s percentage beneficial interest held in us remained at 84%.      
CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member]        
Option exercised in exchange for common stock $ 8,000,000      
CoNCERT Pharmaceuticals, Inc [Member] | Option and License Agreement [Member] | Additional Paid-In Capital [Member]        
Proceeds from royalty receivable $ 8,000,000